CIP
CRL icon

Chartwell Investment Partners’s Charles River Laboratories CRL Stock Holding History

Chartwell Investment Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,126
Closed -$2.31M – 422
2021
Q4 		$2.31M Sell
6,126
-4,521
-42% -$1.76M 0.07% 287
2021
Q3 		$4.39M Hold
10,647
– – 0.14% 218
2021
Q2 		$3.94M Sell
10,647
-9
-0.1% -$3K 0.12% 230
2021
Q1 		$3.09M Sell
10,656
-1,199
-10% -$333K 0.09% 241
2020
Q4 		$2.96M Hold
11,855
– – 0.09% 239
2020
Q3 		$2.69M Sell
11,855
-14
-0.1% -$2.9K 0.1% 236
2020
Q2 		$2.07M Buy
11,869
+37
+0.3% +$5.91K 0.08% 264
2020
Q1 		$1.49M Hold
11,832
– – 0.07% 280
2019
Q4 		$1.81M Sell
11,832
-22
-0.2% -$3.05K 0.06% 299
2019
Q3 		$1.57M Sell
11,854
-36
-0.3% -$4.83K 0.05% 336
2019
Q2 		$1.69M Buy
+11,890
New +$1.61M 0.06% 335
2018
Q1 		– Sell
-54,805
Closed -$6M – 410
2017
Q4 		$6M Sell
54,805
-3,237
-6% -$352K 0.2% 173
2017
Q3 		$6.27M Buy
58,042
+8,014
+16% +$823K 0.21% 163
2017
Q2 		$5.06M Buy
50,028
+186
+0.4% +$17.1K 0.19% 167
2017
Q1 		$4.48M Sell
49,842
-55,338
-53% -$4.7M 0.16% 186
2016
Q4 		$8.01M Sell
105,180
-16,160
-13% -$1.23M 0.27% 132
2016
Q3 		$10.1M Sell
121,340
-41,335
-25% -$3.46M 0.18% 177
2016
Q2 		$13.4M Sell
162,675
-646,260
-80% -$53.2M 0.24% 132
2016
Q1 		$61.4M Buy
808,935
+97,662
+14% +$7.23M 1.16% 23
2015
Q4 		$57.2M Buy
711,273
+296,247
+71% +$21.4M 1.17% 23
2015
Q3 		$26.4M Buy
415,026
+126,466
+44% +$9.08M 0.57% 46
2015
Q2 		$20.3M Sell
288,560
-93,025
-24% -$6.88M 0.4% 75
2015
Q1 		$30.3M Buy
381,585
+118,650
+45% +$8.75M 0.59% 44
2014
Q4 		$16.7M Buy
+262,935
New +$16.5M 0.35% 106

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Chartwell Investment Partners's CRL Position: Q1 2022 in Review

Chartwell Investment Partners sold out of Charles River Laboratories (CRL) in Q1 2022, closing a stake of 6,126 shares — an estimated $2.31M sold.

Chartwell Investment Partners first reported a position in CRL in Q4 2014 and held it in 24 quarters. The position peaked at $61.4M in Q1 2016. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

  • Chartwell Investment Partners reported no remaining Charles River Laboratories position as of Q1 2022 after selling out during the quarter.
  • Chartwell Investment Partners sold 6,126 Charles River Laboratories shares in Q1 2022, an estimated $2.31M.
  • Chartwell Investment Partners first reported a position in Charles River Laboratories in Q4 2014 and held it in 24 quarters.
  • Chartwell Investment Partners's Charles River Laboratories position peaked at $61.4M in Q1 2016.
  • 644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Chartwell Investment Partners's 13F filing for Q1 2022, filed 26 Apr 2022.